Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Everest Medicines Limited
  6. Summary
    1952   KYG3224E1061

EVEREST MEDICINES LIMITED

(1952)
  Report
Delayed Hong Kong Stock Exchange  -  03:08:03 2023-01-27 am EST
27.60 HKD   -3.83%
01/18Everest Medicines Limited Announces Board Changes
CI
01/17Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China
PR
01/17Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
01/18/2023 01/19/2023 01/20/2023 01/26/2023 01/27/2023 Date
23.4(c) 23.15(c) 23.3(c) 28.7(c) 27.6(c) Last
3 854 037 876 148 668 822 1 914 054 1 616 000 Volume
-1.68% -1.07% +0.65% +23.18% -3.83% Change
More quotes
Estimated financial data (e)
Sales 2022 979 M 144 M 144 M
Net income 2022 129 M 19,0 M 19,0 M
Net cash position 2022 2 104 M 310 M 310 M
P/E ratio 2022 -498x
Yield 2022 -
Sales 2023 786 M 116 M 116 M
Net income 2023 -517 M -76,2 M -76,2 M
Net cash position 2023 1 413 M 208 M 208 M
P/E ratio 2023 -13,2x
Yield 2023 -
Capitalization 7 395 M 1 090 M 1 090 M
EV / Sales 2022 5,41x
EV / Sales 2023 7,61x
Nbr of Employees 476
Free-Float 98,7%
More Financials
Company
Everest Medicines Ltd is a China-based company principally engaged in the licensing, clinical development and commercialization of therapies to address critical unmet medical needs. The Company is focusing on the research and development of innovative drug candidate. The Company built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The... 
Sector
Pharmaceuticals
Calendar
03/20Earnings Release
More about the company
Ratings of Everest Medicines Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about EVEREST MEDICINES LIMITED
01/18Everest Medicines Limited Announces Board Changes
CI
01/17Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subj..
PR
01/17Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subj..
CI
01/04Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Full..
AQ
01/03Transcript : Everest Medicines Limited - Special Call
CI
01/03Everest Medicines Aims to Initiate Clinical Trials and File an Emergency Use Authorizat..
CI
2022Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the T..
AQ
2022Everest Medicines to Hold New Corporate Strategy Conference Calls
AQ
2022Calliditas Therapeutics Says China's Center for Drug Evaluation Recommends Kidney Disea..
MT
2022Calliditas Therapeutics JV's Primary IgA Nephropathy Drug Gets Priority Review Recommen..
MT
2022China CDE/NMPA Recommends Priority Review for Everest Medicines's Nefecon for the Treat..
CI
2022Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the T..
CI
2022Everest Medicines Commences Operations at its mRNA Vaccine Manufacturing Facility, Acce..
AQ
2022Everest Medicines Limited Commences Operations at its mRNA Vaccine Manufacturing Facili..
CI
2022Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasim..
PR
More news
News in other languages on EVEREST MEDICINES LIMITED
01/18Everest Medicines Limited annonce des changements au conseil d'administration
01/17Everest Medicines annonce les premières données de l'étude de phase I d'EVER206 sur des..
01/03Everest Medicines vise à lancer des essais cliniques et à déposer une demande d'autoris..
2022Le médicament contre la néphropathie primaire à IgA de Calliditas Therapeutics JV obtie..
2022Le CDE/NMPA de la Chine recommande une revue prioritaire pour le Nefecon d'Everest Medi..
More news
Analyst Recommendations on EVEREST MEDICINES LIMITED
More recommendations
ETFs positioned on EVEREST MEDICINES LIMITEDETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Loncar China BioPharma ETF - Distributing - USD1.23%1.91%China
IShares Core MSCI All Country World ex Cana...0%1.67%World
More ETFs positioned on EVEREST MEDICINES LIMITED
Chart EVEREST MEDICINES LIMITED
Duration : Period :
Everest Medicines Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVEREST MEDICINES LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 23,91 CNY
Average target price 21,36 CNY
Spread / Average Target -10,7%
EPS Revisions
Managers and Directors
Yong Qing Luo Chief Executive Officer & Executive Director
Ian Ying Woo President, CFO & Executive Director
Wei Fu Executive Chairman
Xinhui Hu Chief Technology Officer
Jennifer Yang Chief Scientific Officer
Sector and Competitors